​

Evolus Stock (NASDAQ:EOLS)

ForecastRevenueOwnershipFinancialsChartTranscripts
Evolus by TradingView

Previous Close

$6.72

52W Range

$3.86 - $10.27

50D Avg

$5.68

200D Avg

$5.93

Market Cap

$428.71M

Avg Vol (3M)

$865.22K

Beta

1.33

Div Yield

-

EOLS Company Profile

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

372

IPO Date

Feb 08, 2018

Website

EOLS Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Product$294.96M$264.31M$199.72M
Service$2.22M$1.97M$2.36M

Fiscal year ends in Dec 25 | Currency in USD

EOLS Financial Summary

Dec 25Dec 24Dec 23
Revenue$294.96M$266.27M$202.09M
Operating Income$-32.66M$-34.41M$-49.23M
Net Income$-51.64M$-50.42M$-61.69M
EBITDA$-67.67M$-25.00M$-41.81M
Basic EPS$-0.80$-0.81$-1.08
Diluted EPS$-0.80$-0.81$-1.08

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 04, 26 | 4:30 PM
Q4 25Mar 04, 26 | 4:30 PM
Q3 25Nov 08, 25 | 4:30 PM

Peer Comparison

TickerCompany
TMCITreace Medical Concepts, Inc.
KIDSOrthoPediatrics Corp.
CBLLCeriBell, Inc.
AUTLAutolus Therapeutics plc
QSIQuantum-Si incorporated
NGNENeurogene Inc.
SLDBSolid Biosciences Inc.
TOIThe Oncology Institute, Inc.
EHABEnhabit, Inc.
KMDAKamada Ltd.